MET14外显子跳跃突变非小细胞肺癌的治疗现状

Treatment status of non-small cell lung cancer with METexon14 skipping mutation

MET14外显子(METex14)跳跃突变是非小细胞肺癌(NSCLC)的独立驱动基因。有3%~4%的NSCLC患者携带METex14跳跃突变,此类患者预后差,对于传统化疗、免疫治疗反应欠佳。高选择性MET抑制剂如卡马替尼、特泊替尼、赛沃替尼等在临床试验中显示出良好的有效性及安全性数据,为METex14跳跃突变患者带来新的治疗选择。

MET exon14(METex14)skipping mutation is an independent driver gene in non-small cell lung cancer(NSCLC).About 3%-4% of NSCLC patients carry METex14 skipping mutation.These patients have poor prognoses and poor responses to traditional chemotherapy and immunotherapy.Highly selective MET inhibitors such as capmatinib,tepotinib,savolitinib have shown good efficacy and safety data in clinical trials,which bring new treatment options for patients with METex14 skipping mutations.